BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boëlle PY, Debray D, Guillot L, Clement A, Corvol H; French CF Modifier Gene Study Investigators. Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients. Hepatology 2019;69:1648-56. [PMID: 30058245 DOI: 10.1002/hep.30148] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 De Sutter P, Gasthuys E, Van Braeckel E, Schelstraete P, Van Biervliet S, Van Bocxlaer J, Vermeulen A. Pharmacokinetics in Patients with Cystic Fibrosis: A Systematic Review of Data Published Between 1999 and 2019. Clin Pharmacokinet 2020;59:1551-73. [DOI: 10.1007/s40262-020-00932-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Skov M, Hansen CR, Pressler T. Cystic fibrosis - an example of personalized and precision medicine. APMIS 2019;127:352-60. [PMID: 30761610 DOI: 10.1111/apm.12915] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
3 Wasuwanich P, Karnsakul W. Cystic fibrosis-associated liver disease in children.Minerva Pediatr. 2020;72:440-447. [PMID: 32418413 DOI: 10.23736/S0026-4946.20.05895-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Dana J, Girard M, Franchi-Abella S, Berteloot L, Benoit-Cherifi M, Imbert-Bismut F, Sermet-Gaudelus I, Debray D. Comparison of Transient Elastography, ShearWave Elastography, Magnetic Resonance Elastography and FibroTest as routine diagnostic markers for assessing liver fibrosis in children with Cystic Fibrosis. Clin Res Hepatol Gastroenterol 2021;:101855. [PMID: 34933150 DOI: 10.1016/j.clinre.2021.101855] [Reference Citation Analysis]
5 Singh H, Coffey MJ, Ooi CY. Cystic Fibrosis-related Liver Disease is Associated With Increased Disease Burden and Endocrine Comorbidities. J Pediatr Gastroenterol Nutr 2020;70:796-800. [PMID: 32443033 DOI: 10.1097/MPG.0000000000002694] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Galante GJ. Defining and Treating Cystic Fibrosis Liver Disease: Some Things Old and Some Things New. J Cyst Fibros 2022;21:199-201. [PMID: 35337600 DOI: 10.1016/j.jcf.2022.03.004] [Reference Citation Analysis]
7 Gao E, Hercun J, Heller T, Vilarinho S. Undiagnosed liver diseases. Transl Gastroenterol Hepatol 2021;6:28. [PMID: 33824932 DOI: 10.21037/tgh.2020.04.04] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Dongarwar D, Garcia BY, Miller K, Salihu HM. Assessment of hospitalization rates, factors associated with hospitalization and in-patient mortality in pediatric patients with cystic fibrosis. J Natl Med Assoc 2021:S0027-9684(21)00190-5. [PMID: 34479733 DOI: 10.1016/j.jnma.2021.08.038] [Reference Citation Analysis]
9 Wu Y, Wu Y, Liu K, Liu H, Wang S, Huang J, Ding H. Identification of Genetic Predisposition in Noncirrhotic Portal Hypertension Patients With Multiple Renal Cysts by Integrated Analysis of Whole-Genome and Single-Cell RNA Sequencing. Front Genet 2021;12:775470. [PMID: 34868264 DOI: 10.3389/fgene.2021.775470] [Reference Citation Analysis]
10 Burghard M, Takken T, Nap-van der Vlist MM, Nijhof SL, van der Ent CK, Heijerman HGM, Hulzebos HJE. Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation. Ther Adv Respir Dis 2022;16:17534666211070143. [PMID: 35012387 DOI: 10.1177/17534666211070143] [Reference Citation Analysis]
11 Raynal C, Corvol H. Variant classifications, databases and genotype-phenotype correlations. Arch Pediatr 2020;27 Suppl 1:eS13-8. [PMID: 32172930 DOI: 10.1016/S0929-693X(20)30045-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Zarei K, Meyerholz DK, Stoltz DA. Early intrahepatic duct defects in a cystic fibrosis porcine model. Physiol Rep 2021;9:e14978. [PMID: 34288572 DOI: 10.14814/phy2.14978] [Reference Citation Analysis]
13 Nichols DP, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Sagel SD, Rosenfeld M, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Kirby S, VanDalfsen JM, Clancy JP, Rowe SM. PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy. J Cyst Fibros 2021;20:205-12. [PMID: 33619012 DOI: 10.1016/j.jcf.2021.02.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
14 Ferraioli G, Barr RG, Dillman JR. Elastography for Pediatric Chronic Liver Disease: A Review and Expert Opinion. J Ultrasound Med 2021;40:909-28. [PMID: 32881048 DOI: 10.1002/jum.15482] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Bove KE, Bernieh A, Picarsic J, Cox JP, Yang E, Mantor PC, Thaker A, Lazar L, Sathe M, Megison S. Hypoplasia of Extrahepatic Biliary Tree and Intrahepatic Cholangiolopathy in Cystic Fibrosis Imperfectly Mimic Biliary Atresia in 4 Infants With Cystic Fibrosis and Kasai Portoenterostomy. Am J Surg Pathol 2021;45:1499-508. [PMID: 34510112 DOI: 10.1097/PAS.0000000000001803] [Reference Citation Analysis]
16 Baldissera M, Lewindon PJ, Ramm LE, Hartel GF, Mattiello R, Ramm GA. Advanced but not mild liver disease is a predictor of decreased survival in children with cystic fibrosis, with far greater impact in females: A 27-year real-life cohort study. J Cyst Fibros 2021:S1569-1993(21)02156-1. [PMID: 34949555 DOI: 10.1016/j.jcf.2021.11.015] [Reference Citation Analysis]
17 Mésinèle J, Ruffin M, Kemgang A, Guillot L, Boëlle PY, Corvol H. Risk factors for Pseudomonas aeruginosa airway infection and lung function decline in children with cystic fibrosis. J Cyst Fibros 2021:S1569-1993(21)01422-3. [PMID: 34629287 DOI: 10.1016/j.jcf.2021.09.017] [Reference Citation Analysis]
18 Dana J, Debray D, Beaufrère A, Hillaire S, Fabre M, Reinhold C, Baumert T, Berteloot L, Vilgrain V. Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. J Hepatol 2021:S0168-8278(21)02115-2. [PMID: 34678405 DOI: 10.1016/j.jhep.2021.09.042] [Reference Citation Analysis]
19 Athwal VS, Scott JA, Fitzpatrick E, Rowland M. Emerging clinical perspectives in cystic fibrosis liver disease. Curr Opin Pulm Med 2021;27:593-9. [PMID: 34482340 DOI: 10.1097/MCP.0000000000000824] [Reference Citation Analysis]
20 Martonosi ÁR, Soós A, Rumbus Z, Hegyi P, Izsák V, Pázmány P, Imrei M, Váncsa S, Szakács Z, Párniczky A. Non-invasive Diagnostic Tests in Cystic Fibrosis-Related Liver Disease: A Diagnostic Test Accuracy Network Meta-Analysis. Front Med (Lausanne) 2021;8:598382. [PMID: 34386504 DOI: 10.3389/fmed.2021.598382] [Reference Citation Analysis]
21 Enaud R, Frison E, Missonnier S, Fischer A, de Ledinghen V, Perez P, Bui S, Fayon M, Chateil JF, Lamireau T. Cystic fibrosis and noninvasive liver fibrosis assessment methods in children. Pediatr Res 2021. [PMID: 33731812 DOI: 10.1038/s41390-021-01427-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Hyzny EJ, Chan EG, Morrell M, Harano T, Sanchez PG. A review of liver dysfunction in the lung transplant patient. Clin Transplant 2021;:e14344. [PMID: 33960530 DOI: 10.1111/ctr.14344] [Reference Citation Analysis]
23 Colombo C, Alicandro G. Liver Disease in Cystic Fibrosis: Illuminating the Black Box. Hepatology 2019;69:1379-81. [PMID: 30191579 DOI: 10.1002/hep.30255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Sakiani S, Kleiner DE, Heller T, Koh C. Hepatic Manifestations of Cystic Fibrosis. Clin Liver Dis 2019;23:263-77. [PMID: 30947876 DOI: 10.1016/j.cld.2018.12.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
25 Toledano MB, Mukherjee SK, Howell J, Westaby D, Khan SA, Bilton D, Simmonds NJ. The emerging burden of liver disease in cystic fibrosis patients: A UK nationwide study. PLoS One 2019;14:e0212779. [PMID: 30947265 DOI: 10.1371/journal.pone.0212779] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
26 Colombo C, Alicandro G, Oliver M, Lewindon PJ, Ramm GA, Ooi CY, Alghisi F, Kashirskaya N, Kondratyeva E, Corti F, Padoan R, Asherova I, Evans H, de Monestrol I, Strandvik B, Lindblad A; CF UDCA study group. Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study. J Cyst Fibros 2021:S1569-1993(21)00090-4. [PMID: 33814323 DOI: 10.1016/j.jcf.2021.03.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Cheng K, Rosenthal P, Roberts JP, Perito ER. Liver transplant in children and adults with cystic fibrosis: Impact of growth failure and nutritional status. Am J Transplant 2021. [PMID: 34379865 DOI: 10.1111/ajt.16791] [Reference Citation Analysis]
28 Guo JW, Liu X, Zhang TT, Lin XC, Hong Y, Yu J, Wu QY, Zhang FR, Wu QQ, Shang JY, Lv XF, Ou JS, Zhou JG, Pang RP, Tang BD, Liang SJ. Hepatocyte TMEM16A Deletion Retards NAFLD Progression by Ameliorating Hepatic Glucose Metabolic Disorder. Adv Sci (Weinh) 2020;7:1903657. [PMID: 32440483 DOI: 10.1002/advs.201903657] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
29 Karnsakul W, Wasuwanich P, Ingviya T, Vasilescu A, Carson KA, Mogayzel PJ, Schwarz KB. A longitudinal assessment of non-invasive biomarkers to diagnose and predict cystic fibrosis-associated liver disease.J Cyst Fibros. 2020;19:546-552. [PMID: 32482593 DOI: 10.1016/j.jcf.2020.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Ayoub F, Li H, Blay C, Trillo-Alvarez C, Lascano J, Morelli G. Multidisciplinary Care for Cystic Fibrosis Liver Disease: Where Does the Adult Hepatologist Fit In? Clin Liver Dis (Hoboken) 2019;14:187-90. [PMID: 31879562 DOI: 10.1002/cld.845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
31 Zarei K, Stroik MR, Gansemer ND, Thurman AL, Ostedgaard LS, Ernst SE, Thornell IM, Powers LS, Pezzulo AA, Meyerholz DK, Stoltz DA. Early pathogenesis of cystic fibrosis gallbladder disease in a porcine model. Lab Invest 2020;100:1388-99. [PMID: 32719544 DOI: 10.1038/s41374-020-0474-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Fiorotto R, Strazzabosco M. Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota. Cell Mol Gastroenterol Hepatol 2019;8:197-207. [PMID: 31075352 DOI: 10.1016/j.jcmgh.2019.04.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
33 Woolfson JP, Schreiber RA, Raveendran S, Chilvers M, Barker C, Guttman OR. Role of transient elastography and APRI in the assessment of pediatric cystic fibrosis liver disease. CanLivJ 2021;4:23-32. [DOI: 10.3138/canlivj-2020-0008] [Reference Citation Analysis]
34 Kutney K, Donnola SB, Flask CA, Gubitosi-Klug R, O’Riordan M, McBennett K, Sferra TJ, Kaminski B. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. World J Hepatol 2019; 11(12): 761-772 [PMID: 31966908 DOI: 10.4254/wjh.v11.i12.761] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
35 Sasame A, Connolly L, Fitzpatrick E, Stokes D, Bourke B, Rowland M. The impact of liver disease on mortality in cystic fibrosis - a systematic review protocol. HRB Open Res 2020;3:44. [PMID: 33305166 DOI: 10.12688/hrbopenres.13065.3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 van der Meer R, Wilms EB, Heijerman HGM. CFTR Modulators: Does One Dose Fit All? J Pers Med 2021;11:458. [PMID: 34073663 DOI: 10.3390/jpm11060458] [Reference Citation Analysis]
37 Haq I, Almulhem M, Soars S, Poulton D, Brodlie M. Precision Medicine Based on CFTR Genotype for People with Cystic Fibrosis. PGPM 2022;Volume 15:91-104. [DOI: 10.2147/pgpm.s245603] [Reference Citation Analysis]
38 Sasame A, Connolly L, Fitzpatrick E, Stokes D, Bourke B, Rowland M. The impact of liver disease on mortality in cystic fibrosis - a systematic review protocol. HRB Open Res 2020;3:44. [PMID: 33305166 DOI: 10.12688/hrbopenres.13065.3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Boëlle PY, Debray D, Guillot L, Corvol H; French CF Modifier Gene Study Investigators. SERPINA1 Z allele is associated with cystic fibrosis liver disease. Genet Med 2019;21:2151-5. [PMID: 30739910 DOI: 10.1038/s41436-019-0449-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
40 Mésinèle J, Ruffin M, Guillot L, Boëlle P, Corvol H; on behalf of the French CF Modifier Gene Study Investigators. Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis. JPM 2022;12:252. [DOI: 10.3390/jpm12020252] [Reference Citation Analysis]
41 Escobedo-Monge MF, Barrado E, Alonso Vicente C, Escobedo-Monge MA, Torres-Hinojal MC, Marugán-Miguelsanz JM, Redondo Del Río MP. Copper and Copper/Zinc Ratio in a Series of Cystic Fibrosis Patients. Nutrients 2020;12:E3344. [PMID: 33143143 DOI: 10.3390/nu12113344] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
42 Cuevas-Ocaña S, Laselva O, Avolio J, Nenna R. The era of CFTR modulators: improvements made and remaining challenges. Breathe (Sheff) 2020;16:200016. [PMID: 33304402 DOI: 10.1183/20734735.0016-2020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
43 Scott J, Jones AM, Piper Hanley K, Athwal VS. Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis. Aliment Pharmacol Ther 2022. [PMID: 35048397 DOI: 10.1111/apt.16749] [Reference Citation Analysis]
44 Cipolli M, Fethney J, Waters D, Zanolla L, Meneghelli I, Dutt S, Assael BM, Gaskin KJ. Occurrence, outcomes and predictors of portal hypertension in cystic fibrosis: A longitudinal prospective birth cohort study. Journal of Cystic Fibrosis 2020;19:455-9. [DOI: 10.1016/j.jcf.2019.09.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
45 Debray D, El Mourabit H, Merabtene F, Brot L, Ulveling D, Chrétien Y, Rainteau D, Moszer I, Wendum D, Sokol H, Housset C. Diet-Induced Dysbiosis and Genetic Background Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to Promote Cholangiopathy in Mice. Hepatol Commun 2018;2:1533-49. [PMID: 30556040 DOI: 10.1002/hep4.1266] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
46 Squirell E, Lockyer J. Cystic fibrosis liver disease in Newfoundland and Labrador: a prevalence study. CanLivJ 2021;4:33-7. [DOI: 10.3138/canlivj-2020-0012] [Reference Citation Analysis]
47 Paranjapye A, Ruffin M, Harris A, Corvol H. Genetic variation in CFTR and modifier loci may modulate cystic fibrosis disease severity. J Cyst Fibros 2020;19 Suppl 1:S10-4. [PMID: 31734115 DOI: 10.1016/j.jcf.2019.11.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
48 Dana J, Girard M, Debray D. Hepatic manifestations of cystic fibrosis. Curr Opin Gastroenterol 2020;36:192-8. [PMID: 32097175 DOI: 10.1097/MOG.0000000000000624] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]